drugset / Trial / NCT05952102

Nigella Sativa as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia

NCT05952102

Unknown 104 enrolled Rehab Zaki Elmeazawy
RandomizedParallel-groupDouble-blindTreatment

Summary

Nigella sativa is the world's oldest immunomodulator. The main active component in Nigella sativa is thymoquinone. Research shows thymoquinone has antioxidant, anti-inflammatory, and antimicrobial effects. Based on these observations on the pharmacological activities of Nigella sativa, the potential therapeutic efficacy of N. Sativa was proposed in CAP.

Timeline

Start
2023-08-01
Primary completion
2024-05
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nigella Sativa Oil Traditional medicine (herbal / TCM) 40 mg/kg Oral

Indications

No indication recorded.